1FW2:F:F-WUXI BIOLOGICS-00000083 (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.628

Change

+0.04 (+2.58)%

Market Cap

USD 8.50B

Volume

1.00K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

+2.00 (+1.72%)

USD 525.74B
VX1:F Vertex Pharmaceuticals Incorpo..

-0.35 (-0.09%)

USD 96.61B
RGO:F Regeneron Pharmaceuticals Inc

+3.40 (+0.41%)

USD 92.42B
CSJ:F CSL Limited

+0.68 (+0.41%)

USD 83.77B
CSJA:F CSL LTD SPON.ADR 2

N/A

USD 78.61B
0QF:F Moderna Inc

+2.27 (+2.32%)

USD 38.62B
UNC0:F UCB S.A. UNSP.ADR 1/2

+3.50 (+5.93%)

USD 23.00B
UNC:F UCB SA

+2.20 (+1.83%)

USD 22.90B
1AE:F Argen-X

-4.60 (-1.32%)

USD 20.39B
1AEA:F argenx SE

-4.00 (-1.16%)

USD 20.34B

ETFs Containing 1FW2:F

WDIV:AU SPDR S&P Global Dividend 1.43 % 0.00 %

-0.17 (-0.93%)

USD 0.26B
FGD First Trust Dow Jones Glo.. 0.00 % 0.58 %

+0.20 (+-0.93%)

USD 0.55B
WDIV SPDR® S&P Global Dividen.. 0.00 % 0.40 %

+0.23 (+-0.93%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.49% 8% B- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.49% 8% B- 3% F
Trailing 12 Months  
Capital Gain -71.64% 13% F 6% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return -71.64% 13% F 6% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.48% 30% F 14% F
Dividend Return -10.48% 30% F 13% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.48% 57% F 44% F
Risk Adjusted Return -42.80% 20% F 11% F
Market Capitalization 8.50B 96% N/A 85% B

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.